AdaptHealth raised 2026 revenue guidance after a major strategic partner rollout, but Q1 showed the cost of scale: elevated labor, negative free cash flow and a balance sheet that still needs refinancing execution.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
